Global healthcare company, Novo Nordisk has announced availability of two smart connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus on prescription for diabetic people in the UK.
The two pens record dosing information, including when and how much insulin was administered, and this data can be uploaded to a compatible app, allowing monitoring by patients and their healthcare professionals.
This feature will help facilitate more productive consultations and support personalised treatment guidance, and may also support a longerterm transition from in-person to virtual care, during and after the Covid-19 pandemic.
The product brings a big change as currently insulin injection dosing information is recorded manually.
Emma Wilmot, consultant diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust said: “Integrating innovative technology as a routine part of diabetes care is an important step to improve diabetes care. Novo Nordisk’s smart connected pens are an example of how technology can support people living with diabetes to gain greater insight into the management of their diabetes, on their journey to becoming experts in their diabetes.
“In my clinic, the opportunity to view daily insulin data will allow me to better support the individual with diabetes to achieve their goals. It will allow for more tailored and informed advice on optimisation of glucose levels, with the ultimate goal of improving future outcomes.”
Pinder Sahota, general manager, Novo Nordisk UK, said “We believe digital innovation of devices and treatments has the potential to transform people’s lives and help alleviate the daily burden of living with diabetes. Our smart connected insulin pens aim to empower people to better understand their diabetes management, have more informed conversations with their doctor and ultimately improve their blood glucose control.”
Moreover, the two pens are reusable and in line with Novo Nordisk’s commitment for Zero ambition to have zero environmental impact.
